Hong Kong stock volatility | Junshi Biosciences (01877.HK) surged more than 9%. Positive results were obtained in the Phase III clinical study of JS005 in the treatment of severe plaque psoriasis.

According to the Citic Securities Finance App, Junshi Biosciences (01877.HK) has surged more than 9%, as of the time of writing, rising 8.36% to 38.36 Hong Kong dollars, with a turnover of 173 million Hong Kong dollars.